Similar Search Results

Cost Effectiveness of Long-Acting Risperidone in Sweden

Hensen, Marja; Heeg, Bart; Lothgren, Mickael Lthgren; … - In: Applied Health Economics and Health Policy 8 (2010) 5, pp. 327-341

Background: In Sweden, risperidone long-acting injectable (RLAI) is generally used in a population of schizophrenia … schizophrenia population. Objectives: To analyse the clinical and economic effects of RLAI in the Swedish treatment practice using a …-compliant patient population and the general schizophrenia population. Methods: An existing DES model was adapted to simulate the …

Persistent link: https://www.econbiz.de/10008506287

Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia: A 12- and 24-Month Follow-Up from the e-STAR...

Olivares, Jose M.; Rodriguez-Martinez, Alfonso; Buron, … - In: Applied Health Economics and Health Policy 6 (2008) 1, pp. 41-53

Background: The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment … and lead to improved clinical and economic outcomes for patients with schizophrenia. Objectives: To investigate the cost … effectiveness of treatment with long-acting injectable risperidone compared with previous antipsychotic regimens in patients with …

Persistent link: https://www.econbiz.de/10005590254

Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland: Implications Once Generic Atypicals are Available

Wladysiuk, Magda; Araszkiewicz, Aleksander; Godman, Brian; … - In: Applied Health Economics and Health Policy 9 (2011) 2, pp. 101-110

Introduction: Despite recent concerns over the effectiveness and safety of atypical antipsychotics compared with first …-generation antipsychotics, prescribing of atypical antipsychotics continues to increase. The use of generic atypical antipsychotics is one way … expenditure data for olanzapine and risperidone were provided by the National Health Fund from 2002 to 2006, although no …

Persistent link: https://www.econbiz.de/10010614275

Healthcare Costs of Atypical Antipsychotic Use for Patients with Bipolar Disorder in a Medicaid Programme

Qiu, Ying; Fu, Alex Z.; Liu, Gordon G.; Christensen, Dale B. - In: Applied Health Economics and Health Policy 8 (2010) 3, pp. 167-177

Background: A large body of clinical studies have demonstrated the efficacy of atypical antipsychotic use in the treatment of bipolar disorder. Facing increasing budget pressure, third-party payers, such as state Medicaid programmes in the US, are demanding better understanding of the medical...

Persistent link: https://www.econbiz.de/10008620556

Germany's Decision Rule for Setting Ceiling Prices of Drugs: A Comparative Analysis with Other Decision Rules

Gandjour, Afschin - In: Applied Health Economics and Health Policy 9 (2011) 2, pp. 65-71

In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental...

Persistent link: https://www.econbiz.de/10010614262

The Economics of the NHS Cancer Drugs Fund

Maynard, Alan; Bloor, Karen - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 137-138

Persistent link: https://www.econbiz.de/10010614264

How Cost-of-Illness Studies Can be Made More Useful for Illicit Drug Policy Analysis

Moore, Timothy J.; Caulkins, Jonathan P. - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 75-85

Cost-of-illness (COI) studies seemingly provide a solid foundation for quantifying the potential benefits of illicit drug policy interventions that reduce drug use at the population level. However, their usefulness is severely limited. In this paper, we suggest several improvements to substance...

Persistent link: https://www.econbiz.de/10004990314

To Retain or Remove User Fees?: Reflections on the Current Debate in Low- and Middle-Income Countries

James, Chris D.; Hanson, Kara; McPake, Barbara; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 137-153

Many low- and middle-income countries continue to search for better ways of financing their health systems. Common to many of these systems are problems of inadequate resource mobilisation, as well as inefficient and inequitable use of existing resources. The poor and other vulnerable groups who...

Persistent link: https://www.econbiz.de/10005448953

Community-Based Youth Tobacco Control Interventions: Cost Effectiveness of the Full Court Press Project

Ross, Hana; Powell, Lisa M.; Bauer, Joseph E.; Levy, … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 167-176

Background: We evaluated the impact of a community-based tobacco control project that was implemented in the city of Tucson, Arizona, USA, between 1996 and 2001. Aim: The project's goal was to reduce the prevalence of youth smoking through change in social norms at schools and in communities and...

Persistent link: https://www.econbiz.de/10005448960

Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada

Morgan, Steve; McMahon, Meghan; Mitton, Craig - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 67-73

Drug coverage decisions require information about clinically relevant benefits and risks, as well as economic information about direct and indirect costs, in comparison with relevant treatment alternatives. A recent Canadian initiative aims to improve the evidentiary basis for drug coverage...

Persistent link: https://www.econbiz.de/10005448962

1
2
3
4
5
6
7
8
9
10
Next
Last